Huang Xiaoting, Zhuang Jialing, Yang Yongqiang, Jian Jiaxin, Ai Wen, Liu Chunyong, Tang Wenzhi, Jiang Changyu, He Yongshen, Huang Lesheng, Peng Se
Medical Research Center, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518051, China.
Department of Laboratory Medicine, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai 519015, China.
Biomed Res Int. 2022 Mar 20;2022:3227957. doi: 10.1155/2022/3227957. eCollection 2022.
Serum chitinase-3-like protein 1 (CHI3L1) is a promising marker for diagnosing liver fibrosis. This meta-analysis was carried out to assess the diagnostic performance of serum CHI3L1 for the estimation of liver fibrosis.
Systematic searches were performed on PubMed, Embase, Web of Science, Scopus, the Cochrane Library, Google Scholar, Sinomed, the China National Knowledge Infrastructure (CNKI), the Chinese Medical Journal Database, and the Wanfang databases for available studies. The primary studies were screened strictly according to inclusion and exclusion criteria, and sensitivity, specificity, and other measures of accuracy of serum CHI3L1 for evaluating liver fibrosis were pooled with 95% confidence intervals. was calculated to assess heterogeneity, and sources of heterogeneity were explored by subgroup analysis. Deeks' test was used to assess for publication bias, and likelihood ratio was used to determine posttest probability.
Our research integrated 11 articles, accounting for 1897 patients older than 18 years old. The pooled sensitivity and specificity for significant fibrosis, advanced fibrosis, and cirrhosis were 0.79 and 0.82 with an area under the receiver operating characteristic curve (AUC) of 0.85, 0.81 and 0.83 with an AUC of 0.91, and 0.72 and 0.74 with an AUC of 0.85, respectively. Random-effects models were used to assess for significant heterogeneity, and subgroup analysis showed that age and aetiology of included patients were likely sources of heterogeneity. No potential publication bias was found for serum CHI3L1 in the diagnosis of significant fibrosis, advanced fibrosis, or cirrhosis, and posttest probability was moderate.
Measurement of serum CHI3L1 is a feasible diagnostic tool for liver fibrosis.
血清几丁质酶-3样蛋白1（CHI3L1）是诊断肝纤维化的一个有前景的标志物。本荟萃分析旨在评估血清CHI3L1对肝纤维化评估的诊断性能。
在PubMed、Embase、Web of Science、Scopus、Cochrane图书馆、谷歌学术、中国生物医学文献数据库、中国知网、中国医学期刊数据库和万方数据库中进行系统检索，以查找可用的研究。根据纳入和排除标准严格筛选原始研究，并汇总血清CHI3L1评估肝纤维化的敏感性、特异性及其他准确性指标，并计算95%置信区间。计算I²以评估异质性，并通过亚组分析探索异质性来源。使用Deeks检验评估发表偏倚，并使用似然比确定检验后概率。
我们的研究纳入了11篇文章，涉及1897例18岁以上的患者。显著纤维化、进展性纤维化和肝硬化的合并敏感性和特异性分别为0.79和0.82，受试者工作特征曲线下面积（AUC）为0.85；0.81和0.83，AUC为0.91；0.72和0.74，AUC为0.85。采用随机效应模型评估显著异质性，亚组分析表明纳入患者的年龄和病因可能是异质性来源。在血清CHI3L1诊断显著纤维化、进展性纤维化或肝硬化方面未发现潜在的发表偏倚，检验后概率为中等。
检测血清CHI3L1是一种可行的肝纤维化诊断工具。
